Rebecca A G Christensen, Geoffrey M Anderson, Shana J Kim, Arian Aminoleslami, Jennifer D Brooks
{"title":"遵循乳腺筛查指南与乳腺癌死亡率:一项人口队列研究","authors":"Rebecca A G Christensen, Geoffrey M Anderson, Shana J Kim, Arian Aminoleslami, Jennifer D Brooks","doi":"10.1007/s10549-025-07754-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Population-based breast screening programs diagnose cancers at earlier stage when they are easier to treat. Indeed, individuals screened as part of the Ontario Breast Screening Program (OBSP) are diagnosed with a lower stage of breast cancer than those who have never been screened. We sought to determine if adherence to OBSP guidelines is associated with differences in the rate of death from breast cancer in addition to cancer stage at diagnosis.</p><p><strong>Methods: </strong>48,927 women ≥ 51 years diagnosed with a first primary breast cancer in Ontario 2010-2017 were included and classified as an adherent screener, partial screener, or non-screener. The cohort was developed using administrative health databases linked by Ontario Health. Cause-specific hazard ratios (HR) and 95% confidence intervals (CI) were used to examine the association between adherence to OBSP guidelines and the rate of breast cancer death adjusting for age, rurality, and history of a prior cancer diagnosis. Death from non-breast cancer causes was considered a competing risk.</p><p><strong>Results: </strong>Compared to adherent screenings, non-screeners and non-adherent screeners had higher rates of death from breast cancer (HR: 3.59, 95% CI 3.30-3.90 and HR: 1.69, 95% CI 1.47-1.95 respectively). Further, non-adherent screeners (i.e., screened ≥ once) had a lower rate of breast cancer death than non-screeners (HR: 0.47, 95% CI 0.41-0.54).</p><p><strong>Interpretation: </strong>Individuals screened in the OBSP have a lower rate of death from breast cancer than non-screeners, even if they are not meeting screening guidelines. These findings suggest women should be encouraged to participate in breast screening regardless of their frequency of use.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"63-69"},"PeriodicalIF":3.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259713/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adherence to breast screening guidelines and breast cancer mortality: a population cohort study.\",\"authors\":\"Rebecca A G Christensen, Geoffrey M Anderson, Shana J Kim, Arian Aminoleslami, Jennifer D Brooks\",\"doi\":\"10.1007/s10549-025-07754-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Population-based breast screening programs diagnose cancers at earlier stage when they are easier to treat. Indeed, individuals screened as part of the Ontario Breast Screening Program (OBSP) are diagnosed with a lower stage of breast cancer than those who have never been screened. We sought to determine if adherence to OBSP guidelines is associated with differences in the rate of death from breast cancer in addition to cancer stage at diagnosis.</p><p><strong>Methods: </strong>48,927 women ≥ 51 years diagnosed with a first primary breast cancer in Ontario 2010-2017 were included and classified as an adherent screener, partial screener, or non-screener. The cohort was developed using administrative health databases linked by Ontario Health. Cause-specific hazard ratios (HR) and 95% confidence intervals (CI) were used to examine the association between adherence to OBSP guidelines and the rate of breast cancer death adjusting for age, rurality, and history of a prior cancer diagnosis. Death from non-breast cancer causes was considered a competing risk.</p><p><strong>Results: </strong>Compared to adherent screenings, non-screeners and non-adherent screeners had higher rates of death from breast cancer (HR: 3.59, 95% CI 3.30-3.90 and HR: 1.69, 95% CI 1.47-1.95 respectively). Further, non-adherent screeners (i.e., screened ≥ once) had a lower rate of breast cancer death than non-screeners (HR: 0.47, 95% CI 0.41-0.54).</p><p><strong>Interpretation: </strong>Individuals screened in the OBSP have a lower rate of death from breast cancer than non-screeners, even if they are not meeting screening guidelines. These findings suggest women should be encouraged to participate in breast screening regardless of their frequency of use.</p>\",\"PeriodicalId\":9133,\"journal\":{\"name\":\"Breast Cancer Research and Treatment\",\"volume\":\" \",\"pages\":\"63-69\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259713/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10549-025-07754-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07754-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:以人群为基础的乳腺癌筛查项目在早期诊断癌症,因为早期更容易治疗。事实上,作为安大略省乳腺筛查计划(OBSP)的一部分进行筛查的个体被诊断为乳腺癌的阶段比从未接受过筛查的人低。我们试图确定遵守OBSP指南是否与乳腺癌死亡率的差异以及诊断时的癌症分期有关。方法:纳入安大略省2010-2017年诊断为第一原发性乳腺癌的48,927名≥51岁的女性,并将其分为粘附筛查,部分筛查或非筛查。该队列是利用安大略省卫生部连接的行政卫生数据库开发的。病因特异性风险比(HR)和95%置信区间(CI)用于检查遵守OBSP指南与乳腺癌死亡率之间的关系,调整了年龄、农村地区和既往癌症诊断史。非乳腺癌导致的死亡被认为是一种竞争风险。结果:与粘附筛查相比,非粘附筛查和非粘附筛查的乳腺癌死亡率更高(HR: 3.59, 95% CI 3.30-3.90, HR: 1.69, 95% CI 1.47-1.95)。此外,非依从性筛查者(即筛查≥一次)的乳腺癌死亡率低于非筛查者(HR: 0.47, 95% CI 0.41-0.54)。解释:接受OBSP筛查的个体死于乳腺癌的比例低于未接受筛查的个体,即使他们没有达到筛查指南的要求。这些发现表明,无论使用频率如何,都应该鼓励女性参加乳房筛查。
Adherence to breast screening guidelines and breast cancer mortality: a population cohort study.
Background: Population-based breast screening programs diagnose cancers at earlier stage when they are easier to treat. Indeed, individuals screened as part of the Ontario Breast Screening Program (OBSP) are diagnosed with a lower stage of breast cancer than those who have never been screened. We sought to determine if adherence to OBSP guidelines is associated with differences in the rate of death from breast cancer in addition to cancer stage at diagnosis.
Methods: 48,927 women ≥ 51 years diagnosed with a first primary breast cancer in Ontario 2010-2017 were included and classified as an adherent screener, partial screener, or non-screener. The cohort was developed using administrative health databases linked by Ontario Health. Cause-specific hazard ratios (HR) and 95% confidence intervals (CI) were used to examine the association between adherence to OBSP guidelines and the rate of breast cancer death adjusting for age, rurality, and history of a prior cancer diagnosis. Death from non-breast cancer causes was considered a competing risk.
Results: Compared to adherent screenings, non-screeners and non-adherent screeners had higher rates of death from breast cancer (HR: 3.59, 95% CI 3.30-3.90 and HR: 1.69, 95% CI 1.47-1.95 respectively). Further, non-adherent screeners (i.e., screened ≥ once) had a lower rate of breast cancer death than non-screeners (HR: 0.47, 95% CI 0.41-0.54).
Interpretation: Individuals screened in the OBSP have a lower rate of death from breast cancer than non-screeners, even if they are not meeting screening guidelines. These findings suggest women should be encouraged to participate in breast screening regardless of their frequency of use.
期刊介绍:
Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.